Targeting the red cell enzyme pyruvate kinase with a small allosteric molecule AG-348 may correct underlying pathology of a glycolytic enzymopathy
Open Access
- 31 December 2020
- journal article
- editorial
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (1) , 9-11
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Safety and Efficacy of Mitapivat in Pyruvate Kinase DeficiencyNew England Journal of Medicine, 2019
- Hemoglobin oxidation–dependent reactions promote interactions with band 3 and oxidative changes in sickle cell–derived microparticlesJCI Insight, 2018
- AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiencyBlood, 2017
- Sickle hemoglobin disturbs normal coupling among erythrocyte O2 content, glycolysis, and antioxidant capacityBlood, 2013
- Red cell pyruvate kinase deficiency: molecular and clinical aspectsBritish Journal of Haematology, 2005
- Estimating the prevalence of pyruvate kinase deficiency from the gene frequency in the general white population.2000
- The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphateStructure, 1998
- Erythrocyte Metabolism and Enzyme DefectsLaboratory Medicine, 1996
- Stereochemistry of Cooperative Effects in Haemoglobin: Haem–Haem Interaction and the Problem of AllosteryNature, 1970
- Oxygen-Hemoglobulin Dissociation Curves: Effect of Inherited Enzyme Defects of the Red CellScience, 1969